CARTITUDE-1
The study that showed one CAR-T infusion could keep a third of heavily pretreated myeloma patients progression-free for five years without further treatment.
ORR 98%, sCR 83%; median PFS 34.9 months; at ≥5 years, 33% progression-free with no maintenance (JCO 2025), MRD-negative sustained in most. Movement disorders in ~5% (early cohort).
- 97.9 out of 100 people had their tumour shrink with Cilta-cel.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- 33 out of 100 people alive without the cancer growing at 5 years with Cilta-cel.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- These results apply to the people the trial enrolled: Relapsed/refractory myeloma after ≥3 lines, triple-class exposed: cilta-cel single infusion. People in a different situation may not see the same effect.
- Only 97 people took part, so the numbers are less certain than in a large trial.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- CompanyLegend Biotech
Shares CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma, Ciltacabtagene autoleucel, Multiple myeloma.
- IdeaOne CAR-T infusion instead of autologous transplant
Shares Ciltacabtagene autoleucel, Multiple myeloma, CAR-T cell therapy.
- IdeaPay-for-cure contracts: instalment payments for curative therapies contingent on durable remission
- IdeaMandatory public reporting of vein-to-vein time and failure rate per CAR-T product
- IdeaCollect and freeze T cells at diagnosis for high-risk patients, before chemotherapy
Shares Multiple myeloma, CAR-T cell therapy.
- TrialCARTITUDE-4
Shares Ciltacabtagene autoleucel, Multiple myeloma, CAR-T cell therapy.
- TrialCARTITUDE-5
- InstitutionIUCT Oncopole – Institut Universitaire du Cancer de Toulouse
Shares Ciltacabtagene autoleucel, Multiple myeloma, CAR-T cell therapy.